CCA
NBSE

Catalyst Capital Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Catalyst Capital Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-75
Closed -$75K – 626
2015
Q2 		$75K Hold
75
– – 0.01% 352
2015
Q1 		$76K Buy
+75
New +$248K 0.01% 314

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
HF
Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

Catalyst Capital Advisors's NBSE Position: Q3 2015 in Review

Catalyst Capital Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2015, closing a stake of 75 shares — an estimated $75K sold.

Catalyst Capital Advisors first reported a position in NBSE in Q1 2015 and held it in 2 quarters. The position peaked at $76K in Q1 2015. 47 funds tracked by Wall St. Rank hold NBSE as of Q3 2015.

  • Catalyst Capital Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Catalyst Capital Advisors sold 75 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $75K.
  • Catalyst Capital Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 2 quarters.
  • Catalyst Capital Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $76K in Q1 2015.
  • 47 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Catalyst Capital Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.